Document is current

Article History

Received: 5 August 2024

Accepted: 27 September 2024

First Online: 14 October 2024

Declarations

:

: Peter C. Taylor has received research grants from Galapagos and served as a consultant to Nordic Pharma, Eli Lilly, Pfizer, AbbVie, Gilead and Galapagos (AlfaSigma). Daniela Opris-Belinski served as a consultant to Nordic Pharma, Abbvie, Eli Lilly, Pfizer, UCB, Roche, Sandoz, Ewopharma, Astra Zeneca. Hubert Marotte has received research grants from Celltrion Healthcare, Lilly, MSD, Nordic Pharma, and Novartis; acted as a consultant for AbbVie, BMS, Celltrion Healthcare, Galapagos, Lilly, Medac, Nordic Pharma, Novartis, and Pfizer (ORCID: 0000-0003-1177–9497). Jérôme Avouac received honoraria from Galapagos, Lilly, Pfizer, Abbvie, Bristol-Myers Squibb, Sanofi, Roche-Chugai, Nordic Pharma, Medac, Novartis, Biogen, Fresenius Kabi, Janssen, Celltrion, and MSD. JA recived research grants from Bristol-Myers Squibb, Pfizer (Passerelle), Novartis (Dreamer), Fresenius Kabi, Galapagos and Nordic Pharma. (ORCID: 0000-0002-2463-218X). Alejandro Balsa received grant/research support and fees for consultancies or as a speaker from Abbvie, Amgen, Pfizer, Novartis, BMS, Nordic, Sanofi, Sandoz, Lilly, UCB and Roche. Torsten Witte received honoraria for lectures from AbbVie, Alexion, AMGEN, AstraZeneca, BMS, Celltrion, Chugai, Fresenius Kabi, Galapagos/alfasigma, GSK, Janssen, Lilly, Medac, MSD, Novartis, Octapharma, Pfizer, Roche Pharma, Sanofi, Takeda, UCB. Anne-Barbara Mongey, Mária Filková, Myriam Chebbah, Solenn Le Clanche and Linda A.W. Verhagen have no conflict of interest to declare.

: This article is based on previously conducted studies and does not contain any new studies with human participants or animals performed by any of the authors.